Alpha Teknova Appoints New CMO, Elects Director

Ticker: TKNO · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1850902

Alpha Teknova, Inc. 8-K Filing Summary
FieldDetail
CompanyAlpha Teknova, Inc. (TKNO)
Form Type8-K
Filed DateJul 1, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-election, executive-appointment

TL;DR

Teknova brings in a new CMO and adds a director to the board.

AI Summary

Alpha Teknova, Inc. announced on June 26, 2024, the appointment of Dr. Robert J. Smith as Chief Medical Officer and the election of Ms. Sarah Chen to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, details of which are included in the filing.

Why It Matters

These executive and board changes can signal shifts in the company's strategic direction and leadership, potentially impacting its future growth and operations.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.

Key Players & Entities

  • Alpha Teknova, Inc. (company) — Registrant
  • Dr. Robert J. Smith (person) — Appointed Chief Medical Officer
  • Ms. Sarah Chen (person) — Elected to Board of Directors
  • June 26, 2024 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Robert J. Smith has been appointed as the new Chief Medical Officer.

Who has been elected to the Board of Directors?

Ms. Sarah Chen has been elected to the Board of Directors.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is June 26, 2024.

What is Alpha Teknova, Inc.'s principal executive office address?

The principal executive offices are located at 2451 Bert Drive, Hollister, CA 95023.

What is the SIC code for Alpha Teknova, Inc.?

The Standard Industrial Classification (SIC) code is 2835 for IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.

Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-07-01 16:38:48

Key Financial Figures

  • $0.00001 — ch registered Common Stock, par value $0.00001 per share TKNO The Nasdaq Stock Mar

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALPHA TEKNOVA, INC. Date: July 1, 2024 By: /s/ Stephen Gunstream Stephen Gunstream President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.